Exploratory Studies with BT-11: A Proposed Orally Active Therapeutic for Crohns Disease

International Journal of Toxicology

Volumn 35, Issue 5, 2016, Pages 521-529

  Bissel, Philippe ^a   Boes, Katie ^a   Hinckley, Jonathan ^a   Jortner, Bernard S ^a   Magnin Bissel, Geraldine ^a   Werre, Stephen R ^a   Ehrich, Marion ^a   Carbo, Adria ^b   Philipson, Casandra ^b   Hontecillas, Raquel ^b   Philipson, Noah ^b   Gandour, Richard D ^b   Bassaganya Riera, Josep ^b  

^a VIRGINIA MARYLAND REGIONAL COLLEGE OF VETERINARY MEDICINE   (United States)

^b BIOTHERAPEUTICS INC   (United States)

Author keywords

BT 11; LANCL2; rats; safety; toxicology

Indexed keywords

AGENTS USED IN INFLAMMATORY BOWEL DISEASE; ANTIINFLAMMATORY AGENT; BENZIMIDAZOLE DERIVATIVE; HETEROCYCLIC COMPOUND; PIPERAZINE 1,4 DIYLBIS[[6 (1H BENZO[D]IMIDAZO 2 Y)PYRIDIN 2 YL]METHANONE]; PIPERAZINE DERIVATIVE; UNCLASSIFIED DRUG; LANCL2 PROTEIN, RAT; MEMBRANE PROTEIN; N,N-BIS(BENZIMIDAZOLYLPICOLINOYL)PIPERAZINE;

ABSORPTION RATE CONSTANT; ADULT; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; CROHN DISEASE; DOSE RESPONSE; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG DOSE COMPARISON; DRUG ELIMINATION; DRUG HALF LIFE; DRUG MEGADOSE; DRUG SAFETY; DRUG SCREENING; DRUG SYNTHESIS; DRUG TOLERABILITY; ELIMINATION RATE CONSTANT; EXPLORATORY RESEARCH; HISTOPATHOLOGY; IN VIVO STUDY; MALE; MAXIMUM PLASMA CONCENTRATION; NONHUMAN; PLASMA CONCENTRATION-TIME CURVE; RAT; REPEATED DRUG DOSE; SINGLE DRUG DOSE; TIME TO MAXIMUM PLASMA CONCENTRATION; TREATMENT OUTCOME; VOLUME OF DISTRIBUTION; ANIMAL; ANIMAL BEHAVIOR; BIOASSAY; DISEASE MODEL; DRUG EFFECTS; GENETICS; HALF LIFE TIME; METABOLISM; ORAL DRUG ADMINISTRATION; PRECLINICAL STUDY; SPRAGUE DAWLEY RAT; TANDEM MASS SPECTROMETRY; TOXICITY TESTING;

ADMINISTRATION, ORAL; ANIMALS; BEHAVIOR, ANIMAL; BENZIMIDAZOLES; CROHN DISEASE; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG EVALUATION, PRECLINICAL; ENDPOINT DETERMINATION; HALF-LIFE; MALE; MEMBRANE PROTEINS; PIPERAZINES; RATS; RATS, SPRAGUE-DAWLEY; TANDEM MASS SPECTROMETRY; TOXICITY TESTS;

EID: 84988557286     PISSN: 10915818     EISSN: 1092874X     Source Type: Journal    
DOI: 10.1177/1091581816646356     Document Type: Article

References (16)

1. Stenson WF, Interleukin-4 hyporesponsiveness in inflammatory bowel disease: immune defect or physiological response? Gastroenterology. 1995; 108 (1): 284-286.
2. Bleyer A, O'Leary M, Barr R, Ries LAG, eds. Cancer Epidemiology in Older Adolescents and Young Adults 15 to 29 Years of Age, Including SEER Incidence and Survival: 1975-2000. Bethesda, MD: National Cancer Institute; 2006. NIH Pub. No. 06-5767.
3. Camilleri M,. GI clinical research 2002-2003: the year in review. Clin Gastroenterol Hepatol. 2003; 1 (6): 415-420.
4. Lichtenstein GR, Abreu M, Present D,. Recent Advances in the Treatment of Crohn's Colitis. Killingworth, CT: The Center for Health Care Education, LLC; 2003.
5. Wallace JL, Sharkey KA,. Pharmacotherapy of inflammatory bowel disease. In: Brunton L, Chabner B, Knollman B, eds. Goodman & Gilman's: The Pharmacological Basis of Therapeutics. 12th ed. New York, NY: McGraw Hill Medical; 2011: 1351-1362.
6. Lu P, Hontecillas R, Philipson DW, Basssaganya-Riera J,. Lanthionine synthetase component C-like protein 2: a new drug target for inflammatory diseases and diabetes. Current Drug Targets. 2014; 15 (6): 565-572.
7. Bassaganya-Riera J, Guri AJ, Lu P, Climent M, et al. Abscisic acid regulates inflammation via ligand-binding domain-independent activation of peroxisome proliferator-activated receptor gamma. J Biol Chem. 2011; 286 (4): 2504-2516.
8. PubChem Chemical Information. Web site. http://pubchem.ncbi.nlm.nih.gov/compound/247228#section=Top. Accessed April 26, 2016.
9. Carbo A, Hontecillas R, Cooper J, Gandour RD, Ehrich M, Bassaganya-Riera J,. Lanthionine synthetase C-like receptor 2 (LANCL2): a novel therapeutic target for inflammatory bowel disease. Gastroenterology. 2015; 148 (4): S686-S687.
10. Lu P, Hontecillas R, Horne WT, et al. Computational modeling-based discovery of novel classes of anti-inflammatory drugs that target lanthionine synthetase C-like protein 2. PLoS One. 2012; 7 (4): e34643.
11. Denny KH, Stewart DW,. Acute, sub-acute, sub-chronic and chronic general toxicity testing for preclinical drug development. In: Faqi AS, ed. A Comprehensive Guide to Toxicology in Preclinical Drug Development. Amsterdam, The Netherlands: Elsevier; 2013: 87-105.
12. Food and Drug Administration Center for Drug Evaluation and Research (FDA CDER). Guidance for industry M3(R2) nonclinical safety studies for the conduct of human clinical trials and marketing authorization for pharmaceuticals. 2010. Web site. http://www.fda.gov/downloads/drugs/guidancecomplianceregulatoryinformation/guidances/ucm073246.pdf. Accessed April 26, 2016.
13. Zhang Y, Huo M, Zhou J, Xie S,. PKSolver: an add-in program for pharmacokinetic and pharmacodynamics data analysis in Microsoft Excel. Comp Methods Programs Biomed. 2010; 99 (3): 306-314.
14. Moser VC,. Neurobehavioral screening in rodents. In: Maines MD, ed. Current Protocols in Toxicology. New York, NY: John Wiley & Sons; 1999: 11.2.1-11.2.16.
15. Holford NHG,. Pharmacokinetics and pharmacodynamics: rational dosing and the time course of drug action. In: Katzung BG, Trevor AJ, eds. Basic & Clinical Pharmacology. 13th ed. New York, NY: McGraw Hill Education; 2015: 41-55.
16. Stegemann S, Leveiller F, Franchi D, de Jong H, Linden H,. When poor solubility becomes an issue: from early stage to proof of concept. Eur J Pharm Sci. 2007; 31 (5): 249-261.